Stocks / VRTX

VRTX stock forecast

VERTEX PHARMACEUTICALS INC · Healthcare · Biotechnology

The model's rating

Outperform

VRTX is rated Outperform as of November 18, 2026: its medium-term return forecast is above the middle of the stocks the model scores, but outside the top fifth.

Changed from Greatly Outperform on November 4, 2026.

Premium adds the numeric score behind this label, the medium-term return forecast, and today's full Upfront Picks.

Where this rating comes from: The Upfront Model, whose picks have been recorded with a fingerprint the day they publish since September 18, 2026. See the record.

VRTX is not among the 20 largest holdings published for 2026 Q4. See the portfolio

VRTX against the S&P 500

PeriodVRTXS&P 500 (SPY)
1 month+6.9%-4.7%
3 months-2.8%-4.8%
Year to date+18.3%+7.9%
1 year+23.2%+11.8%

Total return, dividends included.

Key numbers

Price$536.45
Market cap136.01 Billion
P/E (trailing 12 months)34.2
P/S (trailing 12 months)10.5
P/B (latest quarter)6.4
Gross margin85.5%
Net profit margin30.7%
Return on equity20.1%
Beta0.4

As of November 3, 2026.

VRTX and its closest peers

StockCompanyMarket capModel rating
REGN REGENERON PHARMACEUTICALS INC 97.81 Billion Outperform VRTX vs REGN
MRNA MODERNA INC 79.63 Billion Greatly Underperform VRTX vs MRNA
INCY INCYTE CORP 24.01 Billion Greatly Outperform VRTX vs INCY
TECH BIO-TECHNE CORP 11.43 Billion Underperform

Questions

What does the Upfront Investment model say about VRTX?

The model rates VERTEX PHARMACEUTICALS INC (VRTX) "Outperform" as of November 18, 2026, which means its medium-term return forecast is above the middle of the stocks the model scores, but outside the top fifth. The rating is a statistical forecast, not a recommendation to buy or sell.

How is the VRTX rating produced?

A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.

Is VRTX in the Upfront Investment model portfolio?

VRTX is not among the 20 largest holdings published for 2026 Q4.

The rating is generated by The Upfront Model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.